Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;52(3):699-706.
doi: 10.55730/1300-0144.5363. Epub 2022 Jun 16.

Oncometabolites in urine - a new opportunity for detection and prognosis of the clinical progress of verified prostate cancer-a pilot study

Dimitar Delkov  1 , Lyubka Yoanıdu  2 , Desislav Tomov  2 , Rumyana Stoyanova  3 , Ivan Dechev  4 , Yordanka Uzunova  5
Affiliations

Oncometabolites in urine - a new opportunity for detection and prognosis of the clinical progress of verified prostate cancer-a pilot study

Dimitar Delkov et al. Turk J Med Sci. 2022 Jun.

Abstract

Background: Oncometabolites provide a new approach towards the diagnostics and prognosis of the clinical progress of prostate cancer (PCa). This study is about the diagnostic and predictive value of a panel of urinary oncometabolites (ethanolamine, kynurenine, β-alanine, α-alanine, leucine, isoleucine, γ-aminobutyric acid, and sarcosine) and correlation with prostate-specific antigen (PSA) and Gleason score in patients diagnosed with prostate cancer.

Methods: The participants in this cross-sectional study were divided into PCa group (101 patients who matched the including criteria, average age 71) and control group (52 individuals, with no evidence of malignancy, without oncological and other chronic diseases, and without prostate gland pathology, average age 40). The criteria to be included in the PCa group were as follows: i) being diagnosed with prostate cancer, based on digital rectal examination (DRE), prostate ultrasound investigation, or biopsy; ii) not being subjected to a surgical or any other treatment; iii) not having any other concomitant oncological diseases, renal failure, diabetes mellitus. The urinary concentration of the selected metabolites was established through high-performance liquid chromatography with tandem mass spectrometry detection (HPLC-MS/MS).

Results: The comparison of both groups established a significantly different elevated concentration of ethanolamine, sarcosine and kynurenine, and a significantly different decreased concentration of β-alanine and isoleucine in PCa group. No changes of the values were detected in the PCa group with PSA levels below and above 10 ng/mL and Gleason score below and above 6 (p > 0.05). To test whether combination of several variables is more powerful in discriminating between PCa and control group multiple logistic regression analysis was performed. A model including ethanolamine, sarcosine, kynurenine, β-alanine, and isoleucine demonstrated negative predictive power (NPP) 76.2% and positive predictive power (PPP) 81.8%.

Discussion: Urinary concentrations of ethanolamine, sarcosine, kynurenine, β-alanine, and isoleucine in PCa group differ significantly from that of control group. New expanded population studies are needed to discuss our results.

Keywords: Prostate cancer; biomarkers; liquid chromatography with tandem mass spectrometry; oncometabolites.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
Median values with 95% confidence interval of sarcosine (a), ethanolamine (b), β-alanine (c), kynurenine (d) and isoleucine (e) in the control group and the PCa group.
Figure 2
Figure 2
Median values with 95% confidence interval of GABA in patients with high, middle, and low risk of the PCa group. *statistically significant difference between median values.
See this image and copyright information in PMC

References

    1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. 2015;136( 5):e359–e386. doi: 10.1002/ijc.29210. - DOI - PubMed
    1. Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, et al. EAU-ESTRO-SIOG Guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. European Urology. 2017;71( 4):618–629. doi: 10.1016/j.eururo.2016.08.003. - DOI - PubMed
    1. Rigau M, Olivan M, Garcia M, Sequeiros T, Montes M, et al. The present and future of prostate cancer urine biomarkers. International Journal of Molecular Sciences. 2013;14( 6):12620–12649. doi: 10.3390/ijms140612620. - DOI - PMC - PubMed
    1. Tosoian JJ, Trock BJ, Landis P, Feng Z, Epstein JI, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. Journal of Clinical Oncology. 2011;29( 16):2185–2190. doi: 10.1200/JCO.2010.32.8112. - DOI - PubMed
    1. Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. Journal of Urology. 2011;185( 3):869–875. doi: 10.1016/j.juro.2010.10.057. - DOI - PMC - PubMed